People: Ablynx NV (ABLX.BR)
7 Mar 2014
Dr. Edwin Moses, Ph.D., has served as Chief Executive Officer, Member of the Executive Management of Ablynx NV since June 6, 2006. He has also served as Member of the Board of Directors of the Company since 2004. He also served as Chairman of the Board of Directors of the Company between 2004 and 2006, and again between June 6, 2006 and 2013. After he completed his post-doctoral research in Germany, he started his career at Amersham International, Enzymatix and Raggio-Italgene. From 1993 until 2001, he worked at Oxford Asymmetry, first as Chief Executive Officer and later as Chairman until 2001. Apart from and in addition to his duties at the Company, he is Chairman of Lectus Therapeutics Ltd., Chairman of the Board of Capricorn Health-tech Fund (Belgium) and Member of the Board of Directors of the European Biopharmaceutical Enterprises. Furthermore, in the past five years, in addition to Ablynx NV, he has held Board memberships with the following companies: Clinphone Group plc, Fusion IP plc (formerly Biofusion plc), Phoqus Pharmaceuticals Ltd, Pharmaceutical Profiles Ltd, Proimmune Ltd, Paradigm Therapeutics Ltd, Avantium Technologies (the Netherlands), Ionix Pharmaceuticals Ltd, Evotec OAI AG, Bioimage A/S, Inpharmatica Ltd, Prolysis Ltd, ProPharma Ltd, Lectus Therapeutics Ltd and the European Biopharmaceutical Enterprises.
|Total Annual Compensation, EUR||Long-Term Incentive Plans, EUR||All Other, EUR||Fiscal Year Total, EUR|